Factors affecting the purpose suppressive antiviral therapy for patients with recurrent genital herpes
https://doi.org/10.22625/2072-6732-2017-9-2-37-41
Abstract
Objective: To study the factors that influence the destination of suppressive antiviral therapy in patients with recurrent genital herpes doctors of different specialties.
Material and Methods: The study was conducted based on an anonymous survey of professionals providing medical care to patients with genital herpes. The survey involved 67 experts – 44 dermatologist, 13 obstetricians and 10 urologists working in Skin and Venereal Diseases, Women’s consuitation post and Saint Petersburg clinics.
Results: Most respondents indicated that among patients with genital herpes, seeking an appointment, dominated by patients with relapsing nature of the disease. Suppressive antiviral therapy is recommended 68,7% of specialists, including dermatologists 61,3%, 84,6% of obstetricians and gynecologists, and 80% of urologists. The main indications for its experts consider high frequency of relapses, the patient’s tendency to promiscuity, the desire of the patient with fewer relapses, and the emotional response of the patient for the presence of the disease. Do not prescribe suppressive therapy for recurrent genital herpes 31,4% of the doctors surveyed. Among the reasons for which are not appointed by the type of treatment, the patient is dominated by the rejection of this type of treatment, the lack of experience of the destination suppressive therapy, as well as the uncertainty of specialists in its effectiveness.
Conclusion: Suppressive antiviral therapy is recommended 68,7% of specialists. Do not prescribe this type of treatment for recurrent genital herpes 31,4% of the doctors surveyed. The proportion of professionals who refuse the appointment of suppressive antiviral therapy, the highest among dermatologists (38,7% compared with 15,4% among obstetricians and 20% of urologists). The most frequent grounds for refusal from this type of treatment is the lack of confidence in its effectiveness.
About the Authors
I. S. Коlova
Dermatovenerologic dispensary № 4
Russian Federation
Saint-Petersburg
Russian Federation
Saint-Petersburg
I. O. Smirnova
Saint-Petersburg State University
Russian Federation
Saint-Petersburg
Russian Federation
Saint-Petersburg
I. N. Теlichko
Dermatovenerologic dispensary № 4
Russian Federation
Saint-Petersburg
Russian Federation
Saint-Petersburg
Ya. G. Petunova
Saint-Petersburg State University
Russian Federation
Saint-Petersburg
Russian Federation
Saint-Petersburg
References
1. Federal’nye klinicheskie rekomendacii po vedeniju bol’nyh genital’nym gerpesom. Rossijskoe obshhestvo dermatovenerologov i kosmetologov, 2015.
2. Mertz G.J., Schmidt D., Jourden J.L., et al. Frequency of acquisition of first-episode genital infection with herpes simplex virus from symptomatic and asymptomatic source contacts. Sex Transm Dis 1985;12:33-9.
3. Wald A., Warren Т., Ни H., et al. Suppression of subclinical shedding of herpes simplex virus type 2 in the genital tract with valaciclovir [abstract no. H-82]. The 38th Interscience Conference on Antimicrobial Agents and Chemotherapy: 1998 Sep 24-27; San Diego (CA)
4. Corey, L. Sex. Transm. Dis. 1994; 21(Suppl. 2):S38-S44
5. Wald A., Zeh J., Barnum G., et al. Suppression of sub-clinical shedding of herpes simplex virus type 2 with acyclovir. Ann Intern Med 1996;124:8-15
6. Barton SA, et al. Guide to the diagnosis and management of Genital Herpes. UK: Prs Wosby-Wolf 1998.
7. Corey L. The medical importance of genital herpes simplex infection. Recommendations from the IHMF Management Strategies Workshop. France 1997.
8. Herpesvirus Infections: New Paradigms for a New Millenium. In: Focus. Adis International. Australia 2000.
9. Waddell R. Genital HSV infection: long-term approaches for a lifelong disease. Herpesvirus infections: new paradigms for a new millennium. P. 10-17
10. Isakov V.A., Arhipova E.I., Isakov D.V., (Herpesvirus infections of human), rukovodstvo dlja vrachej / pod red. V.A. Isakova. – SPb. : SpecLit, 2013, - 2-e izd., pererab. i dop. – 670 p. : p. 340
11. Kolova I.S., Smirnova I.O. i dr. (The state of medical care for genital herpes and simple blistering), Klinicheskaja dermatologija i venerologija, 2014; 12(5): pp. 98-104
12. Isakov V.A., Isakov D.V. Pathogenesis and treatment of socially significant viral urogenital infections (herpes and papillomavirus infection) // Klinicheskaja farmakologija i terapija, 2014; 23(1): pp. 7-13
13. Butov Ju.S., Malinovskaja V.V., Polesko K.V. (Herpetic infection: pathogenetic rationale for therapy), Materialy konferencii, posvjashhennoj 60-le-tiju kafedry kozhvenboleznej MGSMU. Moskva; 1999. pp. 87-89.
14. Leung D.T., Sacks S.L. Current recommendation for the treatment of Genital Herpes. Drugs, 2000;60:1329-52.
15. Vladimirova E.V., (The effectiveness of valaciclovir in the treatment of recurrent genital herpes): Kliniko-laboratornoe issledovanie: avtoreferat dissertacii kandidata medicinskih nauk: 14.00.11 / Centr. nauchno-issled. kozhno-venerolog. in-t. - Moskva, 1998, p.20.
16. Gilbert LK, Schultz SL, Ebel CW. Genital herpes education and counseling: what are providers providing? Int J STD AIDS 2001; 12: 150–1
17. Patel R, Boselli F, Cairo G, Price M, Wulf HC. Patients’ perspectives on the burden of recurrent genital herpes. Int J STD AIDS 2001; 12: 640–5.
18. Marchant J, Roe A. Genital herpes: recognizing and addressing patients’ needs. Herpes 1997; (4): 36–41.
19. Alexander L. Optimizing the management of genital herpes - patient’s perspective In: Whitley RJ, ed. Optimizing the management of genital herpes. Round Table Series. London: RSM Press 2000:53–8.
Review
For citations:
Коlova I.S., Smirnova I.O., Теlichko I.N., Petunova Ya.G. Factors affecting the purpose suppressive antiviral therapy for patients with recurrent genital herpes. Journal Infectology. 2017;9(2):37-41. (In Russ.) https://doi.org/10.22625/2072-6732-2017-9-2-37-41
Views:
1019
.png)
.png)
Email this article 